Format

Send to

Choose Destination
Clin Pharmacol Ther. 2010 Dec;88(6):751-4. doi: 10.1038/clpt.2010.234.

Payers and the assessment of clinical utility for companion diagnostics.

Author information

1
Government Affairs/Life Sciences, Foley Hoag LLP, Boston, Massachusetts, USA. bquinn@foleyhoag.com

Abstract

The decision makers who approve or deny payment for health-care services review many new technologies. Reimbursement for companion diagnostics for expensive drugs ("personalized medicine") is already under close policy scrutiny, in line with long-standing concerns about overuse of diagnostic tests. Evaluation of diagnostic tests adds some complexities to the payer's comparative-effectiveness evaluation for drugs alone. Currently, decision-making frameworks suitable for companion diagnostics are being developed for practical application by payer policy makers.

PMID:
21081944
DOI:
10.1038/clpt.2010.234
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center